Please select the desired project time frame:
- July 2026
- January 2026
- July 2025
- January 2025
- July 2024
- January 2024
- July 2023
- January 2023
- July 2022
- January 2022
- July 2021
- January 2021
- July 2020
- January 2020
- July 2019
- January 2019
- July 2018
- January 2018
- July 2017
- January 2017
- July 2016
- January 2016
- July 2015
- January 2015
- July 2014
- January 2014
- July 2013
- January 2013
- July 2012
- January 2012
- July 2011
- January 2011
- July 2010
- January 2010
- July 2009
- January 2009
- July 2008
- January 2008
- July 2007
- January 2007
- July 2006
- January 2006
- July 2005
- January 2005
- July 2004
- January 2004
- July 2003
- January 2003
- July 2002
- January 2002
- July 2001
- January 2001
Start of funding 01.01.2009
Large-scale resequencing of 500 nuclear-encoded mitochondrial genes in patients with mitochondrial disorders and Parkinson's disease
Dr. med. Tobias Haack
Ludwig-Maximilians-University of Munich
Neurologische Klinik und Poliklinik im Klinikum München - Großhadern
Prof. Dr. Ronald W. Davis
Stanford University
Stanford Genome Technology Center - Dept. of Biochemistry
Nuclear genes encode the majority of the proteins involved in mitochondrial function and biogenesis and their mutations cause diverse and debilitating clinical disorders. About half of the estimated 1.500 nuclear-encoded mitochondrial proteins have been catalogued in the Mitochondria database MitoP2. However, no feasible systematic tool exists to date to study hundreds of those genes in hundreds of patients. Here, I propose a systematic approach to analyze the DNA sequence of 500 mitochondrial genes in 300 patients with Parkinson’s disease and 200 patients with mitochondrial disorders of unknown aetiology. This project will take advantage of new DNA sequencing technologies developed at the Stanford Genome Technology Center (SGTC). The systematic correlation of newly identified DNA variations and clinical phenotype information will allow the study of genotype-phenotype associations in Parkinson’s disease. Once established, this new approach can then be expanded to study other mitochondrial neurodegenerative diseases.